We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Proenkephalin Assesses True Glomerular Filtration Rate Accurately

By LabMedica International staff writers
Posted on 02 Mar 2020
Print article
Image: The penKid assay allows the measurement of actual kidney function with a simple blood draw. Being non-inferior to the gold standard, rising and decreasing penKid values reveal worsening and improving of kidney function independent from inflammation or any other comorbidity, allowing the inclusion of all critical ill patients (Photo courtesy of SphingoTec GmbH).
Image: The penKid assay allows the measurement of actual kidney function with a simple blood draw. Being non-inferior to the gold standard, rising and decreasing penKid values reveal worsening and improving of kidney function independent from inflammation or any other comorbidity, allowing the inclusion of all critical ill patients (Photo courtesy of SphingoTec GmbH).
The assessment of renal function in clinical practice remains challenging. Using creatinine to assess the glomerular filtration rate (GFR) is notoriously inaccurate, and determination of the true GFR, such as using inulin or iohexol, is laborious and not feasible in daily practice.

Proenkephalin (PENK) is a novel candidate biomarker for kidney function that is filtrated in the glomerulus, shown to represent steady-state GFR in patients with different severities of renal insufficiency and is reliably predictive for acute kidney injury in patients with severe burns. Although AKI is a major complication in critically ill patients, current diagnostic standard methods do not properly and timely diagnose impaired renal function.

Scientists at the Radboud University Medical Center (Nijmegen, the Netherlands) conducted a pilot study in non-steady-state critically ill patients, and compared plasma PENK concentrations with creatinine-based GFR assessments and validated both against the ‘true GFR’ measured using a gold standard method: iohexol plasma clearance.

The investigators included 23 critically ill patients with septic shock. Kidney function was determined using the Modification of Diet in Renal Disease formula (eGFRMDRD), Endogenous Creatinine Clearance (GFRECC), and iohexol plasma clearance (GFRiohexol) during a 6-hour window. Plasma PENK concentrations were measured using the penKid immunoassay (SphingoTec GmbH, Hennigsdorf Germany).

The scientists reported that the eGFRMDRD and GFRECC correlated with the GFRiohexol (R2 = 0.82, p < 0.0001 and R2 = 0.82, p < 0.0001 respectively), however bias and variability were considerable: the eGFRMDRD overestimated the true GFR with 31 ± 35% (95% limits of agreement: -37 to 100%) and the GFRECC with 37 ± 49% (95% limits of agreement: -59 to 133%). Plasma PENK concentrations showed a very strong inverse correlation with the GFRiohexol which tended to be better compared to the correlation of eGFRMDRD and GFRECC with the GFRiohexol.

Andreas Bergmann, PhD, CEO of Sphingotec, commented, "penKid is an early renal function biomarker that is not biased by co-morbidities while reflecting true GFR. penKid has been tested for the first time to identify ICU patients with severe burns that need rapid and aggressive intervention to prevent mortality caused by AKI.”

The authors concluded that in non-steady state critically ill sepsis patients, GFR appears to be more accurately reflected by plasma PENK concentrations compared to conventional creatinine-based methods. Therefore, PENK holds promise as an accurate and feasible biomarker to determine kidney function during non-steady-state conditions in the critically ill. The study was published ahead of print on January 21, 2020 in the journal SHOCK.

Related Links:
Radboud University Medical Center
SphingoTec GmbH


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.